Welcome to our dedicated page for Axim Biotechnologies news (Ticker: AXIM), a resource for investors and traders seeking the latest updates and insights on Axim Biotechnologies stock.
Axim Biotechnologies Inc (AXIM) delivers cutting-edge diagnostic solutions through innovative rapid tests and quantitative assays. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in oncology, ophthalmology, and infectious disease diagnostics.
Access timely press releases covering FDA clearances, clinical trial milestones, and strategic partnerships. Our curated collection includes earnings reports, research breakthroughs, and market expansion announcements – all critical for understanding AXIM's position in biotech innovation.
Key updates feature developments in tear-based diagnostic technology, neutralizing antibody quantification methods, and neurodegenerative disease research. Track progress in proprietary assays that enable precise biomarker measurement from micro-volume samples.
Bookmark this page for structured access to AXIM's verified corporate communications. Regularly updated content helps stakeholders monitor regulatory progress, scientific achievements, and financial performance in the evolving diagnostics sector.
AXIM Biotechnologies has commenced the manufacturing of its proprietary Ocular Immunoglobulin E (IgE) and Lactoferrin diagnostic tests, fulfilling orders from its commercialization partner. The company is producing three separate lots of each assay with a monthly capacity of up to 25,000 units. These point-of-care tests deliver results in just eight minutes and can quantify IgE and Lactoferrin levels, aiding in the diagnosis and treatment of dry eye disease (DED). Approximately 344 million people globally are affected by DED, highlighting the demand for effective diagnostic tools. AXIM's ability to manufacture in-house enhances its quality control and profit margins. This milestone positions AXIM for a more rapid market entry of its diagnostic products and supports its ongoing collaboration with clinicians.
AXIM Biotechnologies has filed a provisional patent with the U.S. Patent and Trademark Office for a proprietary methodology in ocular diagnostic assays. This innovation enables the use of a significantly reduced tear sample size, improving the accuracy and usability of diagnostic tests. Most tests require a tear sample of about 10 microliters, while AXIM’s method only requires 1 microliter, enhancing test sensitivity and specificity. The company plans to integrate this technique into commercially available tests soon. AXIM is also focused on rapid diagnostic solutions for conditions like Dry Eye Disease, an area affecting millions of Americans.
FAQ
What is the current stock price of Axim Biotechnologies (AXIM)?
What is the market cap of Axim Biotechnologies (AXIM)?
